Cambridgeshire -- (MARKET WIRE) -- January 25, 2007 --
For Immediate Release 25 January 2007
BioProgress plc
Arab Health 2007
London, UK, 25 January 2007: BioProgress plc ('BioProgress' or the 'Company')
(AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare announces that
it will be showing its technologies and products at Arab Health, Dubai on 29
January - 01 February.
Arab Health is attended by over 33,000 visitors with 2,200 exhibiting companies.
With many of the global and regional pharmaceutical companies attending, Arab
Health 2007 offers BioProgress a central forum targeting a global audience. We
plan to extend our strategic relationships, and target additional distributors
for our current portfolio of over 40 pharmaceutical and healthcare products, and
five commercialised enabling systems.
For more details on Arab Health 2007, visit
www.arabhealthonline.com.
Steve Martin, Chief Development Officer said:
"Arab Health is an important forum to show our products and technologies to a
wide global audience. This is the first time we have shown at Arab Health and
represents a significant step forward for the company where we are showcasing
over 40 products, and a range of unique enabling drug delivery systems."
For further information:
BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich / Mark Court
About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGEL™polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to
www.bioprogress.com
Forward-Looking Information.
The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies. These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the
expectations contained in the forward-looking statements. The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation. Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company"s filings with the
Securities and Exchange Commission. The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law. Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.
This information is provided by RNS
The company news service from the London Stock Exchange